Description

GLP-2 MAZD

Synthetic bioactive acylated peptide dual agonist of GLP-1R and GCGR (glucagon receptor) derived from oxyntomodulin for in vitro research on dual receptor signaling, intracellular cAMP modulation, hepatic lipid homeostasis, and mitochondrial bioenergetics

Overview & Mechanism of Action (In Vitro)

GLP-2 MAZD (a research code designated for an acylated dual peptide analogue engineered from the oxyntomodulin scaffold with a fatty diacid side chain) is a synthetic polypeptide designed as a balanced, high-affinity co-agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Structural lipid conjugation confers enhanced stability in culture media and resistance to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4). In cellular biochemistry, molecular endocrinology, and hepatic cell biology, it serves as a primary reference standard for studying cross-receptor metabolic crosstalk and energy flux regulation:

• Balanced Dual Co-Agonism (GLP-1R / GCGR): Simultaneous engagement of both G-protein coupled receptors (Gαs) drives additive adenylyl cyclase activation, generating a robust accumulation of intracellular cyclic adenosine monophosphate (cAMP).
• Downstream PKA / CREB & AMPK Pathway Modulation: Elevated cAMP levels stimulate protein kinase A (PKA), triggering downstream phosphorylation cascades that promote fatty acid oxidation and mitochondrial respiratory capacity in primary hepatocyte cultures.
• Suppression of De Novo Lipogenesis in Hepatic Cell Models: Glucagon receptor signaling selectively downregulates key lipogenic transcription programs and enzymes (SREBP-1c, FAS, ACC) under lipid-loading conditions in vitro.
• Cellular Cytoprotection & Endoplasmic Reticulum (ER) Stress Mitigation: GLP-1 receptor activation reduces markers of cellular ER stress and protects target cell lines against lipotoxicity-induced apoptotic pathways.

Technical & Chemical Specifications

• Classification: Research Peptide / Dual GLP-1R & GCGR Co-Agonist (Acylated Oxyntomodulin Analogue)
• Form: Sterile lyophilized white powder (cake)
• Component Identification: Verified via Mass Spectrometry (MS) and analytical HPLC (≥98% purity)
• Recommended Reconstitution Solvent: Sterile bacteriostatic water, sterile deionized water, or sterile phosphate-buffered saline (PBS, pH 7.4–8.0). For optimal dissolution of the acylated lipophilic chain, a mildly alkaline physiological buffer may be utilized.
• Storage Conditions: Store long-term at -20 °C in a dry, dark environment. Following reconstitution, keep refrigerated at 2–8 °C in accordance with standard laboratory protocols.

Scientific References & Literature

• Pocai, A., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses metabolic dysregulation in cellular and preclinical models. Diabetes, 2009.
• Day, J. W., et al. A new glucagon and GLP-1 co-agonist regulates cellular energy flux in experimental in vitro and in vivo models. Nature Chemical Biology, 2009.
• Finan, B., et al. Dual and triple incretin/glucagon receptor agonists: Next-generation metabolic modulators in cellular physiology. Cell Metabolism, 2016.
• Henderson, S. J., et al. Robust anti-steatotic and lipid-clearing actions of a long-acting dual GLP-1R/GCGR peptide in primary hepatocytes. Molecular Metabolism, 2016.

Legal Disclaimer & Terms of Purchase

This product is classified and supplied strictly for laboratory, scientific, and in vitro research purposes only (Research Use Only – RUO). This compound is not a drug, medicine, dietary supplement, cosmetic product, or substance intended for human or veterinary consumption, direct administration, injection, or diagnostic procedures.

By placing an order, the purchaser explicitly confirms that they are at least 18 years of age, possess the requisite professional qualifications and laboratory equipment to safely handle research materials, and are fully conversant with all relevant safety protocols for managing research substances. The seller assumes no liability for any use contrary to these terms.